Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117.
View in:
PubMed
subject areas
Adult
Alanine Transaminase
Antibodies, Monoclonal, Humanized
Aspartate Aminotransferases
Brain
Cohort Studies
Colitis, Ulcerative
Drug Eruptions
Female
Follow-Up Studies
Humans
Immunoglobulin G
Immunosuppressive Agents
Injections, Subcutaneous
Intention to Treat Analysis
Interleukin-2 Receptor alpha Subunit
Longitudinal Studies
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Nasopharyngitis
Pneumonia
Recurrence
Respiratory Tract Infections
Safety
Treatment Outcome
Urinary Tract Infections
authors with profiles
Dusan Stefoski